已发表论文

原发性经皮冠状动脉疾病 STEMI 患者甘油三酯-葡萄糖指数和循环 PCSK9 相关心血管风险的影响:一项前瞻性队列研究

 

Authors Zhao X, Song L, Li J, Zhou J, Li N, Yan S, Chen R , Wang Y, Liu C, Zhou P, Sheng Z, Chen Y, Zhao H, Yan H 

Received 13 September 2022

Accepted for publication 5 December 2022

Published 21 January 2023 Volume 2023:16 Pages 269—282

DOI https://doi.org/10.2147/JIR.S389778

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Ning Quan

Background and Aims: This study aimed to determine whether convertase subtilisin/kexin type 9 (PCSK9)-associated cardiovascular risk is modulated by triglyceride-glucose (TyG) in ST-segment elevation myocardial infarction (STEMI) patients with primary percutaneous coronary disease (PCI).
Methods: A total of 1541 patients with STEMI (aged ≥ 18 years) undergoing primary PCI were consecutively enrolled between March 2017 and March 2019.
Outcomes: When stratifying the overall population according to TyG indices less than or greater than the median (TyG median = 9.07) as well as according to quartiles of PCSK9 levels, higher TyG index levels were significantly associated with all-cause mortality only when TyG levels were 9.07 or higher (ie, relative to quartile 1 [Q1], the adjusted HR for all-cause mortality was 3.20 [95% CI, 0.54– 18.80] for Q2, = 0.199; 7.89 [95% CI, 1.56– 40.89] for Q3, = 0.013; and 5.61 [95% CI, 1.04– 30.30] for Q4, = 0.045. During a median follow-up period of 1.96 years, the HR for all-cause mortality was higher in the subset of patients with TyG ≥median and PCSK9 ≥median (p for trend = 0.023) among those with type 2 diabetes mellitus (T2DM). However, there were no statistically significant differences among the subgroups. Among T2DM patients with a TyG index greater than the median, the Kaplan-Meier curve showed that patients with the highest PCSK9 levels had an increased risk of all-cause mortality (log-rank = 0.017) and cardiac-cause mortality (log-rank = 0.037) compared with lower PCSK9 quartile levels.
Conclusion: Elevated PCSK9 levels are related to all-cause mortality and cardiac-related mortality when TyG levels are greater than the median, but not when levels are less than the median. This suggests a potential benefit of lowering circulating PCSK9 levels in STEMI patients with insulin resistance.
Keywords: triglyceride glucose index, proprotein convertase subtilisin/kexin type 9, mortality, type 2 diabetes, ST-segment elevation myocardial infarction, primary percutaneous coronary intervention